| Name | Title | Contact Details |
|---|
At Inipharm, we`re building on novel insights and applying our chemistry expertise to develop therapies for patients with liver disease. Inipharm`s lead program is focused on small-molecules to target the activity of HSD17B13, a highly validated, genetically defined target for multiple severe liver and related diseases.
Aptinyx Inc. (formerly Naurex Inc.) is a biopharmaceutical company focused on discovery and development of transformative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering compounds that enhance synaptic plasticity, or strengthen the network for neural cell communication. Molecules discovered by Aptinyx achieve this through a novel mechanism that modulates NMDA receptors, resulting in drugs that are both highly effective and well tolerated. This mechanism has applicability across a number of brain and nervous system disorders. Aptinyx is rapidly advancing promising drug candidates into clinical development for indications with high unmet medical need.
Foxtag Enterprises is a Rockledge, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Leading Research into Solving one of the World`s Largest Drivers of Disease: Inflammation
Aptus Genomics is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.